OHRP—A placebo-adjusted VA improvement of 4.1 letters (less than one line on the eye chart) with a p-value of 0.18 does not strike me as a great outcome.
This program does not deserve to advance to phase-3, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.